Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

International journal of hematology - 1 Nov 2010

Tsujimura Akane, Kiyoi Hitoshi, Shiotsu Yukimasa, Ishikawa Yuichi, Mori Yumiko, Ishida Hiroshi, Toki Tsutomu, Ito Etsuro, Naoe Tomoki

Abstract excerpt

Activating mutations of KIT play an important role in the pathophysiology of several human malignancies, including acute myeloid leukemia. Activated KIT kinase is therefore a promising molecular target for the treatment of many malignancies harboring KIT activation. Here we examined the potency o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to K562 Cells

Share to Leukemia, Myeloid, Acute

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 20890793
DOI: 10.1007/s12185-010-0692-8

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20890793-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.PMID 20890793Read ↗

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition.Semantic proximity Read ↗

Heat Shock Protein 90 Inhibition in Imatinib-Resistant Gastrointestinal Stromal TumorSemantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsSemantic proximity Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.Semantic proximity Read ↗

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.Semantic proximity Read ↗

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor.Semantic proximity Read ↗

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.